Scandinavian Distributor of Medical Diagnostic and Life Science Products

Corporate Governance

Biotech-IgG AB applies the Swedish Code of Corporate Governance ("the Code") in those parts that are relevant for the company. The Code complements the external rules which affect the Corporate Governance, which is constituted mainly by the Companies Act, Accountancy legislation and current listing agreement. Biotech-IgG AB applies fiscal financial year 1 Jan - 31 Dec, and will account for any deviations from the Code in a Corporate Governance report which will be attached to the Annual Report for 2016. These documents are available for downloading:

Board

The Biotech-IgG Board consists of the following persons: Mats Andersson, Stefan Nyman and Aram Soma



Management

Glenn Renhult, CEO/VD Biotech-IgG AB 


Sana Noor, Office Manager Biotech-IgG A/S 


Protocols general annual meetings

Protocols annual general meetings (in Swedish)

20172016201520142013201220112010, 2009, 2008, 2007, 2006


Protocols extra general meetings (in Swedish)

201620162015-12015-2201420132012, 2011-1, 2011-2, 2011-3


Next annual general meeting will be held May 9, 2018. All shareholders, independent of the number of shares in possession, has the possiblity to get issues handled in a general meeting provided they are presented to the board in such good time that they may be part of the notice for the general meeting. Such issues should therefore have been received by the board latest six weeks before the general meeting is held.

Corporate governance report  (SE)


Full proposal for extraordinary general meeting of 9 November 2017. Download PDF


Auditor

Isabella Eva Rummer


Bringer Revision AB 

Investor relations contact

Glenn Renhult

glenn.renhult@biotech-igg.com